Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors
Tumors harboring BRAF class III (BRAF vIII) mutations comprise a novel subset with distinct genomic heterogeneity. BRAF vIII mutations may sensitize tumors to anti-EGFR treatments. BRAF vIII alterations show significantly less co-occurrence with alterations that predict resistance to anti-EGFR agents. Rare tumors with limited therapy options should be screened for BRAF vIII mutations as they may benefit from anti-EGFR agents.
Authors
- Mutlu Demiray (ORCID: https://orcid.org/0000-0003-2501-3097)
- Benjamin G. Kaplan
- Ünal Metin Tokat (ORCID: https://orcid.org/0000-0003-0026-368X)
- Jiancheng Hu (ORCID: https://orcid.org/0000-0003-1615-0030)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Ashkan Adibi (ORCID: https://orcid.org/0000-0002-0505-1558)
- Smruthy Sivakumar
- Ethan S. Sokol (ORCID: https://orcid.org/0000-0002-2988-0537)
- Esranur Aydın (ORCID: https://orcid.org/0000-0001-7850-0177)
- Eylül Özgü (ORCID: https://orcid.org/0000-0002-6264-1546)
- Ebru Gül Karakoç
Institutions
- Medical College of Wisconsin (US)
- National Cancer Centre Singapore (SG)
- Istanbul Memorial Hospital (TR)
- WIN Consortium
- Foundation Medicine (United States)
Publication Details
- Journal
- BJC Reports
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1038/s44276-024-00086-2
- Citations
- 6
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.40